Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1676-1681

  Leung, Thomas W T ^a,c   Patt, Yehuda Z ^b   Lau, Wan Yee ^a   Ho, Stephen K W ^a   Yu, Simon C H ^a   Chan, Anthony T C ^a   Mok, Tony S K ^a   Yeo, Winnie ^a   Liew, Choong Tsek ^a   Leung, Nancy W Y ^a   Tang, Amanda M Y ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; METOCLOPRAMIDE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032765871     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hong Kong Cancer Registry Ed. Hong Kong Hospital Authority, p.17, 1992.
2. Okuda, K. Primary liver cancers in Japan. Cancer (Phila.), 45: 2663-2672, 1980.
3. Lee, N. W., Wong, J., and Ong, G. B. The surgical management of primary carcinoma of the liver. World J. Surg., 6: 66-75, 1982.
4. Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer (Phila.), 56: 918-928, 1985.
5. Nerenstone, S. R., Ihde, D. C., and Friedman, M. A. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat. Rev., 15: 1-31, 1988.
6. Hochster, H. S., Green, M., Speyer, J., Fazzini, E., Blum, R., and Muggia, F. M. 4′-Epidoxorubicin (Epirubicin): activity in hepatocellular carcinoma. J. Clin. Oncol., 11: 1535-1540, 1985.
7. Falkson, G., Ryan, L. M., Johnson, L. A., Simson, I. W., Coetzer, B. J., Carbone, P. P., Creech, R. H., and Schutt, A. J. A randomized phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: an ECOG study. Cancer (Phila.), 60: 2141-2145, 1987.
8. Carr, B. I., Iwatsuki, S., Baron, R., Jain, A., Selby, R., Madariaga, J., and Barnes, J. Intrahepatic arterial cisplatinum and doxorubicin with or without lipiodol for advanced hepatocellular carcinoma (HCC): a prospective randomized study. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 12: A668, 1993.
9. Lai, C. L., Lau, J. Y., Wu, P. C., Ngan, H., Chung, H. T., Mitchell, S. J., Corbett, T. J., Chow, A. W., and Lin, H. J. Recombinant interferon-α in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology, 17: 389-394, 1993.
10. Elias, L., and Crissman, H. A. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res., 48: 4868-4873, 1988.
11. Wadler, S., Schwartz, E. L., Goldman, M., Lyver, A., Rader, M., Zimmerman, M., Itri, L., Wienberg, V., and Wiernik, P. H. Fluorouracil and recombinant α-2A-interferon: an active regimen against advanced colorectal carcinoma. J. Clin. Oncol., 7: 1769-1775, 1989.
12. Patt, Y. Z., Yoffe, B., Charnsangavej, C., Pazdur, R., Fischer, H., Cleary, K., Roh, M., Smith, R., Noonan, C. A., and Levin, B. Low serum α-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-α-2b. Cancer (Phila.), 72: 2574-2582, 1993.
13. Stuart, K., Tessitore, J., and Huberman, M. 5-Fluorouracil and α-interferon in hepatocellular carcinoma. Am. J. Clin. Oncol., 19: 136-139, 1996.
14. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO, 1979.
15. Simon, R. How large should a phase II trial of a new drug be? Cancer Treat. Rep., 71: 1079-1085, 1987.
16. Patt, Y. Z., Charnsangavej, C., Yoffe, B., Smith, R., Lawrence, D., Chuang, V., Carrasco, H., Roh, M., Chase, J., and Fischer, H. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J. Clin. Oncol., 12: 1204-1211, 1994.
17. Pelletier, G., Roche, A., Ink, O., Anciaux, M. L., Derhy, S., Rougier, P., Lenoir, C., Attali, P., and Etienne, J. P. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J. Hepatol., 11: 181-184, 1990.
18. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N. Engl. J. Med., 332: 1256-1261, 1995.
19. Lau, W. Y., Ho, S., Leung, W. T., Chan, M., Ho, R., Johnson, P. J., and Li, A. K. C. Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intra-arterial infusion of yttrium-90 microspheres. Int. J. Radiat. Oncol. Biol. Phys., 40: 3, 583-592, 1998.
20. Lai, C. L., Wu, P. C., Chan, G. C., Lok, A. S., and Lin, H. J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer (Phila.)., 62: 479-483, 1988.
21. Filler, R. M., Ehrlich, P. F., Greenberg, M. L., and Babyn, P. S. Preoperative chemotherapy in hepatoblastoma. Surgery, 110: 591-596, 1991.
22. Ninane, J., Perilongo, G., Stalens J-P., Guglielmi, M., Otte, J-B., and Mancini, A. Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: a SIOP pilot study. Med. Pediatr. Oncol., 19: 199-203, 1991.
23. Ng, I. O. L., Lai, E. C. S., Fan, S. T., Ng, M. M. T., and So, M. K. P. Prognostic significance of pathologic features of hepatocellular carcinoma. Cancer (Phila.), 76: 2443-2448, 1995.